You are here: Industry Insights > ovarian

News List

Pivotal phase III trial launched in recurrent ovarian cancer europeanpharmaceuticalreview
March 26, 2019
INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer…
‘Trojan horse’ cancer drug shows promise in multiple tumour types pharmaphorum
February 14, 2019
A new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.
Phase II Clinical Trials of DCVAC Show Significant Benefit for Patients with Ovarian and Lung Cancer b3cnewswire
June 20, 2018
SOTIO, a biotechnology company owned by the PPF Group, presented results from its Phase II clinical trials evaluating DCVAC, an active cellular immunotherapy product,
Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation worldpharmanews
May 23, 2018
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.
Research identifies marker for aggressive ovarian cancer pharmafile
April 27, 2017
Scientists have identified a marker which they believe can inform whether a tumour will become more aggressive and...
Pipeline Drug Offers Promise in Treatment of Platinum-Resistant Ovarian Cancer americanpharmaceuticalreview
April 19, 2017
According to research and consulting firm GlobalData, mirvetuximab soravtansine, a drug currently in the trial phase by ImmunoGen, has the potential to solve an unmet medical need for patients with platinum-resistant ovarian cancer.
AZ’ Lynparza hits targets in ovarian cancer trial pharmatimes
March 17, 2017
AstraZeneca has unveiled data from a late-stage trial showing that Lynparza improved progression free survival (PFS) in ...

Previous page 1 2 Next page